By contrast, patients with HER2-enriched breast cancer have elevated ERBB2 and those with luminal breast cancers have elevated ESR1 and PGR. As expected, these trends were all confirmed in bulk transcriptomes, clarified in TC transcriptomes and absent in TAC transcriptomes (Fig. 1d). This evidence concerns the gene ESR1 and breast cancer.